TY - JOUR
T1 - The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá
AU - Van Duin, Mark JM
AU - Conde, Rafael
AU - Wijnen, Ben
AU - Evers, Silvia MAA
AU - Gonzalez-Rodriguez, Javier L.
AU - Govers, Mark JG
AU - Hiligsmann, Mickaël
PY - 2017/5/4
Y1 - 2017/5/4
N2 - Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia. Methods: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogotá to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs. Results: Of all patients, 72% experienced CMs; of these, half experienced ≥2 CMs (N = 49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P = 0.022) was applied among patient with ≥2 CMs. No statistical significance was found for the impact of CMs on costs. Conclusion: This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.
AB - Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia. Methods: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogotá to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs. Results: Of all patients, 72% experienced CMs; of these, half experienced ≥2 CMs (N = 49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P = 0.022) was applied among patient with ≥2 CMs. No statistical significance was found for the impact of CMs on costs. Conclusion: This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.
UR - http://www.scopus.com/inward/record.url?scp=84992413355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992413355&partnerID=8YFLogxK
U2 - 10.1080/14737167.2017.1246185
DO - 10.1080/14737167.2017.1246185
M3 - Article
C2 - 27730842
AN - SCOPUS:84992413355
SN - 1473-7167
VL - 17
SP - 1
EP - 8
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 03
ER -
